Background Analysis: US FDA Advisory Committee to Review Intellipharmaceutics’ Proposed Abuse-Deterrent, Extended-Release Oxycodone Report
Background Analysis: US FDA Advisory Committee to Review Intellipharmaceutics’ Proposed Abuse-Deterrent, Extended-Release Oxycodone Report